The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis
1 other identifier
observational
100
1 country
1
Brief Summary
Background: Psoriasis is a chronic, immunologically-mediated, inflammatory skin disease and targeted therapies e.g. tumor necrosis factor (TNF)-α and TH-17 antagonists have become increasing important agents in the management of psoriasis. TNF, interleukin-17 (IL-17) and TH-17 play major roles in defense against infection. Large-scaled clinical trials and post-marking surveillance had shown these agents may increase susceptibility to infections. Most studies evaluate the reactivation of tuberculosis but the influence of targeted therapies on the viral infection has not been extensively investigated. TNF-α has been shown to contribute to the killing of cytomegalovirus (CMV)- and human papillomaviruses (HPV)-infected cells. Additionally, recent studies have shown a high prevalence of HPV DNA in psoriatic skin and increased HPV5 antibodies in patients with psoriasis. The prevalence of HPV in the skin was also affected by therapeutic modalities, such as psoralen-ultraviolet A (PUVA). Several case reports in which CMV, Epstein-Barr virus (EBV) and HPV infection complicated therapy with TNF-α antagonists have been reported. However, the study investigated the effect of TNF-α antagonists and other biologics on reactivation of latent viruses is limited. Only two studies investigated the short-term effect of infliximab on reaction of herpesviruses in patients of rheumatoid arthritis and Crohn's disease. The high prevalence of combination use of immunosuppressants, such as methotrexate alongside with TNF-α antagonists in these patients is different from patients with psoriasis. Additionally, various bacterium and fungi, such as Staphylococcus aureus, Malassezia are associated with provocation and/or exacerbation of psoriasis and recent studies had shown IL-17 is essential for the immune response to common fungus Candida albicans. Aim: The aim of this study is to prospectively investigate the effect of target therapies (TNF-α, TH-17 antagonist, IL-17 antagonists, tofacitinib and apremilast) on the activation of viruses, including CMV, EBV and HPV and the impact of biologics on the prevalence of surface colonization of microorganism, including HPV, bacteria and fungi, in patients with psoriasis. Methods and procedures: Our project consists of two related study. The first (Study 1), a prospective observational study, included patients with psoriasis who are going to undergo biologics therapy, the viral loads of CMV and EBV, HPV DNA detection in eyebrow hairs and skin scales, and bacterial, fungal cultures from skin scales were performed before the initiation, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies. This part of our project is to investigate the dynamic effect of biologics on the microorganisms in patients with psoriasis. The second part (Study 2), a case control study, recruits psoriasis patients who have started target therapies, they receive the sampling of blood, eyebrow hairs and skin scales for CMV, EBV and HPV investigations when they are enrolled. Control group compromised of age-and disease severity-matched psoriasis patients who are not treating with target therapies or other systemic antipsoriatic agents. Comparison of the prevalence of latent virus, virus reactivation, bacteria and fungi skin colonization between psoriasis patients who are treating with and without target therapies is performed. The aim of study 2 was to assess any difference of the status of latent virus or microorganism colonization in skins between psoriasis patients treated with and without target therapies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 3, 2011
CompletedFirst Posted
Study publicly available on registry
January 5, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedJanuary 5, 2012
July 1, 2011
3.9 years
August 3, 2011
January 2, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Changes from baseline in viral loads of human papillomaviruses virus during and after target therapy
Study 1:The sampling of eyebrow hairs and skin scales before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies. Study 2: The same above mentioned microorganisms exams were done at enrollment and repeated again 12 weeks after the discontinuation of therapies. Comparison of the prevalence of latent virus and changes from baseline in viral load of human papillomaviruses virus between psoriasis patients who are treating with and without target therapies is performed.
before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies
Changes from baseline in viral loads of cytomegalovirus during and after target therapy
Study 1:The sampling of blood before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies. Study 2: The same above mentioned microorganisms exams were done at enrollment and repeated again 12 weeks after the discontinuation of therapies. Comparison of the prevalence of latent virus, and changes from baseline in viral load of cytomegalovirus between psoriasis patients who are treating with and without target therapies is performed.
before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies
Changes from baseline in viral loads of Epstein-Barr virus during and after target therapy
Study 1:The sampling of blood before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies. Study 2: The same above mentioned microorganisms exams were done at enrollment and repeated again 12 weeks after the discontinuation of therapies. Comparison of the prevalence of latent virus, and changes from baseline in viral load of Epstein-Barr virus between psoriasis patients who are treating with and without target therapies is performed.
before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies
Secondary Outcomes (1)
Changes from baseline in the prevalence of bacterial and fungal skin colonization during and after target therapy
before the initiation of biologics therapy, 12 and 24 weeks after initiation of the target therapies, 12 weeks after discontinuation of target therapies.
Study Arms (3)
Study 1 goup
Patients who are planned to receive targeted agents
Study 2 case group
Patients who have received targeted therapy
study 2 control group
Psoriasis patients without target therapy
Eligibility Criteria
We include patients with psoriasis who will receive and who are currently on target therapies,such as TNF-α, TH17,and IL-17 antagonists for psoriasis, in a tertiary referral centre in northern Taiwan (National Taiwan University Hospital (NTUH)) between 2011 and 2015.
You may qualify if:
- Clinical diagnosis of psoriasis/psoriatic arthritis and are going o receive target therapies in the near future
- Age more than 20 years old
- Will receive target therapies for psoriasis/psoriatic arthritis
- Willing to receive blood, hair and skin scale sampling
You may not qualify if:
- Pregnancy
- Not candidates for topical therapies, such as :
- Active tuberculosis or HIV, human papillomaviruses, cytomegalovirus infection, Epstein-Barr virus infection Evidence of latent tuberculosis but refuse to receive isoniazid prophylaxis Have malignancy required for chemotherapy or radiotherapy Active uncontrolled hepatitis -Have received phototherapy, systemic immunosuppressants or target therapies within 14, 30, 84 days prior to enrollment, respectively Study 2 (case group)
- Clinical diagnosis of psoriasis/psoriatic arthritis
- Age more than years old
- Have received target therapies for more than 3 months
- willing to receive blood, hair and skin scale sampling
- Pregnancy
- Not candidates for topical therapies, such as :
- Active tuberculosis or HIV, human papillomaviruses, cytomegalovirus infection, Epstein-Barr virus infection Evidence of latent tuberculosis but refuse to receive isoniazid prophylaxis Have malignancy required for chemotherapy or radiotherapy Active uncontrolled hepatitis
- Have received phototherapy, or systemic immunosuppressants within 14 and 30 days prior to enrollment,respectively Study 2 (control group)
- Clinical diagnosis of psoriasis/psoriatic arthritis and are going o receive target therapies in the near future
- Age more than 20 years old
- Willing to receive blood, hair and skin scale sampling
- Without phototherapy, systemic immunosuppressants or target therapies within 84 days prior to enrollment, respectively
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan University Dermatology department
Taipei, 100, Taiwan
Biospecimen
Serum and skin scales
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Tsen-Fang Tsai, M.D.
National Taiwan University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 3, 2011
First Posted
January 5, 2012
Study Start
July 1, 2011
Primary Completion
June 1, 2015
Study Completion
June 1, 2015
Last Updated
January 5, 2012
Record last verified: 2011-07